Clinical Report: Correction to the Author Byline in a Study of First-Trimester Inhaled Corticosteroid Use

Overview

A correction to the byline of a study on first-trimester inhaled corticosteroid (ICS) use in women with asthma changed Hoon Kim’s credentials from MS, PhD to MD, PhD. The notice does not report changes to the study’s methods or findings.

Background

Asthma management during pregnancy involves consideration of both medication exposure and the risks of poorly controlled disease. The GINA 2026 report states that the advantages of actively treating asthma during pregnancy markedly outweigh potential risks of usual asthma medications, and that ICS use is not associated with an increased incidence of fetal abnormalities. The correction notice concerns author credentials in a study of ICS continuation during the first trimester, rather than a change to its clinical results.

Data Highlights

The correction notice reports no numerical or clinical outcome data. It corrects Hoon Kim’s credentials from MS, PhD to MD, PhD in the Original Investigation, “Inhaled Corticosteroids Continuation During First-Trimester Pregnancy and Outcomes Among Women With Asthma.”

Key Findings

• The corrected Original Investigation was published on August 24, 2026.
• The correction changes Hoon Kim’s credentials from MS, PhD to MD, PhD.
• The notice identifies the study as “Inhaled Corticosteroids Continuation During First-Trimester Pregnancy and Outcomes Among Women With Asthma.”
• The supplied correction notice does not describe changes to the study’s methods, results, or conclusions.
• GINA 2026 states that ICS use is not associated with an increased incidence of fetal abnormalities and that the advantages of actively treating asthma during pregnancy markedly outweigh potential risks of usual asthma medications.

Clinical Implications

This notice is a bibliographic correction and does not itself alter the clinical interpretation of the study. GINA 2026 provides the broader guidance that asthma should be actively treated during pregnancy and that indicated ICS therapy is not associated with an increased incidence of fetal abnormalities.

Conclusion

The correction updates Hoon Kim’s credentials in the study byline. No change to the study’s clinical content is reported in the notice.

Related Resources & Content

1. JAMA Network Open, 2026 — Inhaled Corticosteroids Continuation in the First Trimester and Pregnancy Outcomes in Women With Asthma
2. Global Initiative for Asthma, 2026 — GINA Strategy Report 2026
3. JAMA Network Open — Correction of Author Attribution in the Study on Prenatal Azithromycin and Neurodevelopmental Disorder Risk in Children
4. Drug Safety — Investigating the Association Between Acid-Suppressive Medications During Pregnancy and Childhood Asthma Risk: A Bidirectional Crossover Analysis Utilizing the General Practice Research Database
5. Intensive Care Medicine — Correction Notice: Impact of Hydrocortisone on Mortality Rates in Severe Community-Acquired Pneumonia Patients
6. The Journal of Clinical Endocrinology & Metabolism — Amendment to: “Investigating Maternal-Fetal Metabolic Interactions in Pregnancies Complicated by Polycystic Ovary Syndrome”
7. Inhaled Corticosteroids Continuation in the First Trimester and Pregnancy Outcomes in Women With Asthma
8. GINA Strategy Report 2026
9. GINA Strategy Report 2026 Front Cover
10. First-trimester asthma controller medication use and major congenital malformation risk in offspring of women with asthma: A nationwide population-based cohort study.